Background: Numerous studies have shown that there are links between obesity, liver fat and the gut microbiome. However, there are mixed results on whether probiotics could impact the gut microbiome and/or help to decrease liver fat and obesity outcomes.
Introduction
According to the Center for Disease Control and Prevention, the prevalence of adolescent obesity is 21.9% among Hispanic populations in the United States (1) . These high rates of obesity can lead to numerous comorbidities including non-alcoholic fatty liver disease (NAFLD). NAFLD is a major chronic liver disease that can progress to non-alcoholic steatohepatitis (NASH) and is a risk factor for a variety of metabolic impairments such as type 2 diabetes (2,3). While weight loss and dietary sugar restriction has been proposed for liver fat reduction, these strategies rely on volitional behavioural changes that may be difficult to sustain over the long-term. Thus, other approaches need to be identified to prevent NAFLD and related metabolic impairments among at-risk children and adolescents. Effective treatments are especially needed for obese Hispanic youth, who have a greater susceptibility to obesity and the accumulation of liver fat compared with other racial/ethnic groups (4, 5) .
Emerging work in both animal and human models suggests a role for the gut microbiome in the aetiology of liver fat accumulation and other metabolic abnormalities associated with obesity and type 2 diabetes (6, 7) . It has been suggested that a obesogenic gut microbiota harvests more dietary energy, which leads to increased body mass (8) and may have a negative impact on gut hormones (7) . Therefore, the gut microbiome presents a potential target for combating obesity and obesityrelated diseases such as NAFLD.
Studies have shown that probiotic supplementation attenuated liver and abdominal fat accumulation in obese rats fed a high-fat diet (9) (10) (11) (12) . In a study among Italian children with NASH, VSL#3 probiotic supplementation decreased body mass index (BMI) and NASH severity and increased circulating levels of the satiety hormone glucagon-like peptide-1 (GLP-1) compared with placebo (13) . In a recent metaanalysis of nine randomized controlled trials, probiotics were effective at improving blood lipids and insulin sensitivity among patients with NAFLD (14) . These findings highlight probiotic supplementation as a potential therapeutic strategy for reducing overall adiposity and liver fat in humans. However, to our knowledge, no studies have examined whether VSL#3 supplementation has the ability to reduce obesity, liver fat and fibrosis, metabolic markers and/or gut hormones among high-risk Hispanic youth. Furthermore, no studies have examined whether probiotic supplementation results in detectable changes in the relative abundance of bacteria in the gut in a population of Hispanic adolescents. Therefore, the aim of this study was to conduct a 16-week double-blind, randomized placebo-controlled clinical trial in obese Hispanic adolescents in order to determine if VSL#3 ® treatment reduced adiposity, liver fat and liver fibrosis or altered fasting levels of insulin, glucose and/or gut hormones (e.g. GLP-1, ghrelin and peptide YY).
Methods

Study design
Nineteen obese Hispanic adolescents (12-18 years of age) completed a 16-week parallel, double-blind and placebo-controlled trial examining the efficacy of probiotic supplementation in changing gut microbiota and gut-derived appetite regulating hormones as primary outcomes. Body composition, liver fat and liver fibrosis, plasma levels of insulin and glucose and food intake were also measured as secondary outcomes.
We randomly assigned participants to one of two intervention groups: a treatment group that received daily supplementation of an active probiotic culture called VSL#3 ® (probiotic, n = 8), or a control group that received daily supplementation with a matched, inactive product (placebo, n = 11) (Data S1). Participants consumed these supplements three times per day for 16 weeks. Noncaloric, sugar-free flavoured drinks (vitaminwater zero) were provided by the study team as the vehicle for consuming the supplements. Adherence and side effects were monitored via scheduled phone calls to the participants and via reporting logs. Outcomes measures and covariates were assessed at study entry and after 16-18 weeks of consuming the supplements. On occasions where participants could not make the 16-week visit, we scheduled their appointment within 2 weeks, and the participants continued supplementation until that date; thus, the intervention lasted up to 18 weeks for some participants.
Participants
We recruited obese Hispanic adolescents from communities surrounding University of Southern California (USC) who met the following inclusion criteria: (i) age 12-18 years, (ii) BMI percentile ≥95th for age and gender; (iii) self-identified Hispanic ethnicity; and (iv) post-puberty as determined by self-assessed of Tanner stage ≥4. Participants were excluded for any of the following: (i) diagnosis of any disease known to influence insulin action and secretion (including type 1 and type 2 diabetes); (ii) involvement in a weight loss, exercise or sports programme within 6 months prior to participation; (iii) use of medication known to influence body composition or fat distribution, insulin resistance, gut function or lipid profiles; (iv) history of renal/liver disease or any disease affecting liver fibrosis and steatosis; (v) diagnosis/current treatment for celiac, inflammatory bowel syndrome, Crohn's disease or other major gastrointestinal issues; (vi) any other disease that could compromise the immune system; (vii) current pregnancy; and (viii) current smoking (more than one cigarette in the past week or ≥200 cigarettes in lifetime) or use of other recreational drugs. Because antibiotics can impact the gut microbiome, we further excluded participants if they had used antibiotics within 30 d prior to study participation. Prescription of more than 1 week of antibiotics during the intervention also served as a withdrawal criterion.
Procedures
After an overnight fast for a minimum of 10 h, participants arrived at the Diabetes and Obesity Research Institute at the USC between 7:00-9:00 am for their clinical visit. A registered physician conducted a medical exam to confirm participants' eligibility and health status. The participants self-assessed pubertal development using a diagrammatic representation of Tanner staging adapted from Marshall and Tanner (15) . We conducted all study measures, see Data S1, at the beginning of the intervention to establish baseline and repeated measures at the end of the intervention to determine the effectiveness of the intervention. Briefly, a stool sample and fasting blood draw were collected to characterize the gut microbiota and measures fasting levels of insulin, glucose and gut hormones. A dual energy X-ray absorptiometry scan was performed to assess body composition, and a whole abdominal magnetic resonance imaging scan was used to measure liver fat and fibrosis (Data S1). Parental consent and child assent was obtained prior to any testing procedure. The USC's Institutional Review Board approved all research. The trial was initially registered before the start of the trial under https://prstest.nlm.nih.gov that was a test site for clinicaltrials.gov. This trial is now registered at clinicaltrials.gov as NCT03115385.
Gut microbiota analysis
We collected stool samples using commercial collection kits developed by Second Genome (South San Francisco, CA, USA) that contained a preservative, and the samples were stored at À80°C immediately after receipt. If a participant was unable to provide the stool sample in person at the study visit, then the study team provided a prepaid envelope containing the collection kit, so the participant could mail their sample to the lab within 1-2 d of the study visit; all samples were received at the lab within 5 d of the visit. The relative abundance of bacterial taxa was determined using 16S rRNA amplicon sequencing conducted by Second Genome. Briefly, nucleic acid isolation was performed with the MoBio PowerMag ® Microbiome kit (Carlsbad, CA, USA) according to manufacturer's guidelines and optimized for highthroughput processing. All samples were quantified via the Qubit ® Quant-iT dsDNA High Sensitivity Kit (Invitrogen, Life Technologies, Grand Island, NY, USA) to ensure that they met minimum concentration and mass of DNA. To enrich the sample for bacterial 16S V4 rDNA region, DNA was amplified utilizing V4 fusion primers described by Caporaso et al. (16) .
The complete sequences of the primers were Forward -5 0 GTGCCAGCMGCCGCGGTAA 3 0 and Reverse -5 0 GGACTACHVGGGTWTCTAAT 3 0 . Samples met the post-polymerase chain reaction quantification minimum and were advanced for pooling and sequencing on the Illumina Miseq v3 sequencer platform. The 16S rDNA sequence reads were quality filtered, clustered into operational taxonomic units (OTUs) with a shared 97% identity by UPARSE (de novo OTU clustering), and a representative consensus sequence per de novo OTU was aligned against the Greengenes reference database (version 13.5) (17) and assigned taxonomy to determine community profiles. The UPARSE clustering algorithm comprises a chimaera filtering and discards likely chimeric OTUs. All non-strain sequences that passed the quality filtering were mapped to the representative consensus sequences to generate an abundance table for de novo OTUs. The raw 16S rRNA sequence reads used for this study are available on the National Center for Biotechnology Information Short Read Archive associated with the National Center for Biotechnology Information Bioproject PRJNA421553 (https://www. ncbi.nlm.nih.gov/bioproject/PRJNA421553).
Blood assays and dietary recalls
Blood samples were collected after a 10-h overnight fast. These samples were collected in green top tubes (glucose and insulin) and black top tubes (active and total ghrelin, active GLP-1 and peptide YY) that both contained spray-dried K 2 -ethylenediaminetetraacetic acid anticoagulant and proprietary protease inhibitors that perform similarly to a dipeptidyl peptidase-IV inhibitor (BD Biosciences, San Jose, CA, USA). Green top tubes were immediately centrifuged with black tops being centrifuged immediately after the green tops. The samples were centrifuged at 2000 g for 15 min at 4°C. Plasma was aliquoted into separate cryovials for each analyte. The plasma samples were then stored at À80°C until analysis in which the plasma was analysed using enzyme-linked immunosorbent assay kits from EMD Millipore Corp. (St. Charles, MO, USA). Plasma glucose was assayed in duplicate using the glucose oxidase method and a Yellow Springs Instrument 2300 analyser (YSI Inc., Yellow Springs, OH, USA). Insulin was assayed in duplicate using the Millipore enzyme-linked immunosorbent assay kits.
To assess daily energy intake, 24-h diet recalls were performed in duplicate (first in person, other by telephone) using the 'multiple-pass' method and analysed using the Nutrition Data System for Research software 
Statistical analysis
Distributions of trial outcomes were assessed for normality, and when data were not normal, we transformed the data to fit a normal distribution. Independent t-tests were used to confirm that both groups were matched on the primary study measures at baseline. Unless otherwise noted, all comparisons used the Welch t-test statistic ('unequal variances' ttest), which is considered the best approach for contrasting small, independent samples where unequal variances are assumed. Chi-squared analysis was used to confirm that the groups did not significantly differ in gender distribution. For gut microbiota analysis, we log-normalized sequence read counts of each taxonomic group to account for varying sequencing depths across samples as well as meet the assumptions of normality using the following equation:
Log 10 taxa i counts in sample j total counts in sample j ÃAverage counts per sample þ 1 :
Taxa were retained if there was a total read count of at least 1000 across samples and were present in at least 25% of samples. Changes in adiposity, metabolic measures and gut microbiota across the intervention were examined using multivariate linear models where the independent variable was treatment (VSL#3 or placebo). Baseline t-tests indicated that the groups significantly differed in BMI at the start of the study (p = 0.04), so baseline BMI was included as a covariate in these analyses. Sex and change in energy intake was also used as covariates.
Linear models were used to assess the effect of probiotic vs. placebo supplementation on BMI, waist circumference, fat mass, fat free mass, adiposity (%), liver fat fraction and liver fibrosis across the 16-week study period. We also assessed changes in the gut appetite regulating hormones and gut microbiota abundance using linear models. Results are presented as the mean change ± standard error (M ± SE) unless otherwise stated. All statistical analyses were performed in R statistical package version 3.3.1 with a priori significance level set at p < 0.05 (18) . 
Results
Participant characteristics
Twenty-seven participants were recruited between March 2015 and November 2015 with 25 being randomized to either probiotic or placebo arm using an adaptive stratified block design (see Data S1). Of the 25 adolescents initially enrolled in this study, one participant was deemed ineligible due to a low Tanner development stage, one participant withdrew before completing the intervention, two participants were excluded for antibiotic-use and one participant was excluded for probable diabetes (i.e. baseline fasting blood glucose >126 mg dL À1 (19) ). The final sample size was n = 19, and the CONSORT diagram is shown in Fig. 1 . The participants experienced no severe adverse events during the intervention. The baseline participant characteristics are shown in Table 1 . Independent t-tests confirmed that both groups were similar for age, weight, height, body composition, liver fat, liver fibrosis, fasting blood levels, and self-reported energy and macronutrient intake before beginning the intervention. Baseline BMI was significantly greater in the placebo group (p = 0.04) compared with the probiotic group and, thus, was included as a covariate in the statistical analyses reported in the succeeding text. Chi-squared confirmed that the groups did not significantly differ in gender distribution (p = 0.58).
Effect of the intervention on the gut microbiota, gut hormones and fasting blood measures
When comparing the microbiota of the placebo and probiotic treatment groups before intervention for each microbe and for overall diversity indices, there appeared to be significant (significance defined by a p < 0.05 and at a 10% false discovery rate) differences in the gut microbiota of the two groups at baseline. Because of pre-intervention differences, we performed linear models for each of the microbes adjusting for baseline abundance and baseline BMI. When we conducted a multidimensional scaling at the family-level taxonomic classifications using BrayCurtis dissimilarity metric, we found that the intervention had no effect on the overall composition of the gut microbes or individual microbes at all taxonomic levels ( Fig. 2) (Table 2 ). There were no significant effects of treatment on changes in leptin, active or total GLP-1, total ghrelin and peptide YY ( Table 2 ). In addition, fasting glucose and insulin were not significantly affected by treatment ( Table 2) .
Effects of intervention on body composition and liver measurements
The effects of the intervention on body composition outcomes are summarized in Table 3 . As shown in Table 3 , participants in the VSL#3 ® group exhibited a significant increase in adiposity across time, whereas the placebo group exhibited a decrease in adiposity. These findings were independent of baseline BMI, sex and change in energy intake. Separate analyses of total body fat, trunk fat and lean mass confirmed that changes in fat percentage were specifically due to alterations in fat mass, which increased for participants in the VSL#3 ® group. These alterations in body composition were accompanied by an increase in BMI in the VSL#3 ® group relative to the placebo group. Waist circumference was not significantly dependent upon treatment. There were no significant effects of treatment on visceral or subcutaneous adiposity. There was no evidence that probiotic supplementation altered liver fat percentage or liver fibrosis. We also observed that treatment with VSL#3
® did not result in any significant changes in energy intake of dietary macronutrients. Full detailed results of pre and post measures of all outcomes are shown in Supplemental Tables Data S1 and Data S2.
Discussion
Previous studies suggest that VSL#3 ® supplementation may improve liver fat, NASH, adiposity and alter gut hormones (13) . To our knowledge, no studies have examined the efficacy of VSL#3 ® supplementation among obese Hispanic adolescents who are at increased risk for obesity and NAFLD. Further, it is currently unknown how VSL#3 ® supplementation may impact gut microbial diversity and/or relative abundance. Therefore, the aim of this study was to determine if a probiotic supplementation with VSL#3 ® would alter the gut microbiota and/or obesity-related outcomes, including liver fat, in obese Hispanic adolescents. Overall probiotic supplementation did not alter the gut microbiota or fasting glucose or insulin levels. However, VSL#3 ® supplementation resulted in an increase of total and trunk adiposity in the absence of any changes in reported dietary intake or gut hormones related to appetite.
To our knowledge, this is the first study to show that VSL#3 ® supplementation may lead to increased adiposity in an obese population. There has been various studies that have shown that treatment with various Lactobacillus species has been associated with weight gain in animals and lean adults (20) . Yet, previous studies in overweight or obese adults have shown that probiotics lead to weight loss or have no effects on body weight (21-23). It is important to note that the current work was modelled after a 16-week probiotic supplementation intervention study in obese (≥85 BMI percentile) Italian children (ages 9-12) with NASH using the same VSL#3 ® formulation (13) . Results from the Alisi et al. study showed that the severity of NASH and BMI was decreased in the probiotic compared with the placebo group. Their study also found that ® supplementation leads to decreases in adiposity, our study provides evidence that there may be differential responses to probiotic supplementation across individuals as a function of age, obesity status and/or race/ethnicity.
In the current study, VSL#3 ® compared with placebo did not alter the composition of the gut microbiota. Because there were no changes in the gut microbiota over the intervention, it is unlikely that changes in the gut bacterial abundance contributed to increased adiposity. However, it is possible that the functional potential of the gut microbiota was altered and that future studies should perform untargeted metagenomics or metaproteomics in order to examine this possibility. Even further, we found that the 16S rRNA sequence reads assigned to the same taxonomic classification as the bacteria in VSL#3 ® (Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum subsp. longum, Bifidobacterium longum subsp. infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei and Lactobacillus delbrueckii subsp. bulgarius) were only observed in the stool sample of one participant in the VSL#3 ® group. The lack of sequence reads that map to the bacteria in VSL#3 ® suggests that these bacteria were not at a detectable level to observe any changes after the intervention. The sequence reads that were used were extracted from the V4 region of the 16S rRNA gene, and this region has been shown to be highly sensitive in differentiating species-level bacteria in VSL#3 ® (24) . Although this study is strengthened by its randomized controlled study design, detailed measures of body composition, fasting blood measures and the gut microbiota, it is limited by its small sample size. Because of increases in adiposity and termination of funding, the intervention was ended prior to enrolling 20 participants in each arm. At our intended sample size, the power to detect intervention differences of 6.8% in liver adiposity would have been 81%. With our current sample size, this power falls to 47% that can make us underpowered to detect differences in change of liver fat percentage. This could be a reason that we do not detect a significant change in gut microbiota, but this is not certain as we did not do a power analysis for changes in gut microbiota (there are no other studies that examine the impact of VSL#3 ® on the gut microbiota of youth, so there is limited data for a power analysis for changes in gut microbiota). This study is also limited by the use selfreported dietary recalls, which may have limited our ability to detect small changes in energy intake that could may have contributed to increased adiposity over the course of the intervention. Although unlikely, it is possible that unmeasured decreases in physical activity contributed to the weight in the treatment group over the study period. Also, it must be noted that the participants used vitaminwater zero as a means for delivery of probiotic or placebo up to three times a day. The beverage contains erythritol and stevia leaf extract as sweeteners. A study by Suez et al. (25) showed that consumption of artificial sweeteners (including saccharin-based, sucralose-based or aspartame-based) could increase glucose intolerance in mice and humans. Our beverage does contain the artificial sweeteners erythritol and stevia, and to our knowledge, there are no studies examining the impact of these sweeteners on gut microbiota, so little is known about how these sweeteners could affect gut microbiota in these adolescents. Despite these possible limitations, this is the first to examine the effects of probiotic supplementation in Hispanic adolescents, who are at increased risk for obesity and NAFLD. Importantly, results from this study suggest that this population may have undesired responses to probiotics, which should be investigated larger and more racially and ethnically diverse study populations.
In conclusion, results from this study show that a 16-week probiotic supplementation with VSL#3 ® significantly increased total adiposity among obese Hispanics adolescents in the absence of alterations in the gut microbiota. Additionally, VSL#3
® supplementation also did not alter liver fat, gut hormones or fasting measures of glucose or insulin among minority youth at high risk for NAFLD. Additional studies are needed to determine the mechanisms by which VSL#3 ® supplementation may lead to increased adiposity in this population, and further research could help to guide what populations could benefit from the protective effects of probiotics against obesity.
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